MRAI - Marpai, Inc. Stock Price, Fair Value and News

2.10USD+0.08 (+3.96%)Market Closed

Market Summary

USD2.10+0.08

Market Closed

3.96%

MRAI Stock Price

View Fullscreen

MRAI RSI Chart

MRAI Valuation

Market Cap

21.6M

Price/Earnings (Trailing)

-0.89

Price/Sales (Trailing)

0.62

EV/EBITDA

-0.42

Price/Free Cashflow

-1.69

MRAI Price/Sales (Trailing)

MRAI Profitability

EBT Margin

-70.31%

Return on Equity

167.12%

Return on Assets

-80.51%

Free Cashflow Yield

-59.11%

MRAI Fundamentals

MRAI Revenue

Revenue (TTM)

34.9M

Rev. Growth (Yr)

-23.65%

Rev. Growth (Qtr)

-15.18%

MRAI Earnings

Earnings (TTM)

-24.2M

Earnings Growth (Yr)

51.02%

Earnings Growth (Qtr)

13.55%

Breaking Down MRAI Revenue

Last 7 days

-6.2%

Last 30 days

-15.3%

Last 90 days

56.7%

Trailing 12 Months

-16.9%

How does MRAI drawdown profile look like?

MRAI Financial Health

Current Ratio

0.82

MRAI Investor Care

Shares Dilution (1Y)

42.12%

Diluted EPS (TTM)

-2.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	34.9M	0	0	0
2023	27.8M	32.3M	36.1M	37.2M
2022	16.8M	19.3M	21.8M	24.3M
2021	0	0	0	14.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Marpai, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 07, 2024	lamendola damien	bought	1,501,500	1.65	910,000	chief executive officer
Jan 17, 2024	dendy michael charles	acquired	-	-	50,000	-
Jan 17, 2024	calabrese jennifer rosario	acquired	-	-	50,000	-
Jan 17, 2024	pons robert m	acquired	-	-	50,000	-
Jan 16, 2024	lamendola damien	bought	1,012,110	0.9201	1,100,000	chief executive officer
Jan 16, 2024	eitan yaron	bought	193,221	0.9201	210,000	-
Jan 16, 2024	pons robert m	bought	11,133	0.9201	12,100	-
Jan 11, 2024	powers john paul	acquired	-	-	150,000	president
Dec 14, 2023	lamendola damien	bought	295,500	1.97	150,000	chief executive officer
Dec 14, 2023	pons robert m	bought	21,901	1.81	12,100	-

Which funds bought or sold MRAI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	33,030	33,030	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	18.95	2,639	6,647	-%
May 15, 2024	Cubist Systematic Strategies, LLC	sold off	-100	-129,568	-	-%
May 15, 2024	STATE STREET CORP	unchanged	-	14,150	50,037	-%
May 14, 2024	OMERS ADMINISTRATION Corp	new	-	28,060	28,060	-%
May 14, 2024	NORTHERN TRUST CORP	new	-	54,651	54,651	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	6.18	35,785	110,273	-%
May 13, 2024	UBS Group AG	added	8,156	23,167	23,370	-%
May 10, 2024	JPMORGAN CHASE & CO	sold off	-100	-65.00	-	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	66,924	236,660	-%

Are Funds Buying or Selling MRAI?

Are funds buying MRAI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRAI

No. of Funds

Unveiling Marpai, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	lamendola damien	40.4%	4,146,597	SC 13D/A
Feb 13, 2024	altium capital management lp	0%	0	SC 13G/A
Jan 19, 2024	eitan yaron	7.7%	720,902	SC 13D/A
Jan 19, 2024	lamendola damien	34.3%	3,236,597	SC 13D/A
Dec 18, 2023	lamendola damien	28.5%	2,306,631	SC 13D/A
Nov 28, 2023	lamendola damien	27.6%	2,156,631	SC 13D/A
Nov 24, 2023	eitan yaron	5.9%	2,471,535	SC 13D/A
Apr 26, 2023	altium capital management lp	6.2%	1,805,327	SC 13G
Aug 29, 2022	lamendola damien	34.1%	7,046,384	SC 13D/A
Aug 23, 2022	lamendola damien	32.7%	6,754,129	SC 13D/A

Recent SEC filings of Marpai, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	144	Notice of Insider Sale Intent
May 14, 2024	144	Notice of Insider Sale Intent
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	8-K	Current Report
May 10, 2024	144	Notice of Insider Sale Intent
May 10, 2024	144	Notice of Insider Sale Intent
May 10, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Marpai, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

Marpai, Inc. News

Latest updates

Marpai, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	-15.2%	7,385,000	8,706,874	8,729,152	10,046,980	9,672,045	7,628,454	4,938,105	5,556,506	6,218,809	5,509,030	4,799,251	3,531,512
Costs and Expenses	-17.4%	11,450,000	13,862,103	15,757,435	17,317,668	18,194,827	16,568,314	10,752,561	12,220,438	11,757,416	11,645,353	9,535,008	7,502,559
S&GA Expenses	-45.4%	602,000	1,102,535	1,842,018	1,473,311	2,179,117	2,108,795	1,053,814	2,216,788	1,559,116	1,932,443	1,588,981	1,122,665
R&D Expenses	-66.3%	7,000	20,785	267,269	523,432	500,209	1,024,054	781,750	1,309,157	593,107	615,773	568,817	285,363
EBITDA Margin	13.5%	-0.55	-0.64	-0.76	-0.81	-0.93	-0.95	-0.94	-1.00	-1.02	-0.97	-	-
Interest Expenses	-6.4%	398,000	425,404	383,756	333,279	385,010	259,363	2,908	562	3,945	42,614	108,503	92,621
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-150,000
Earnings Before Taxes	18.3%	-4,346,000	-5,317,189	-7,295,380	-7,556,620	-8,872,849	-9,055,216	-5,779,860	-6,664,782	-5,489,664	-5,728,668	-4,792,579	-4,021,974
EBT Margin	10.1%	-0.70	-0.78	-0.91	-0.97	-1.09	-1.11	-1.08	-1.18	-1.20	-1.13	-	-
Net Income	13.5%	-4,346,000	-5,027,051	-7,295,380	-7,556,620	-8,872,849	-8,534,084	-5,779,860	-6,664,782	-5,489,664	-5,728,668	-4,792,579	-3,871,974
Net Income Margin	10.2%	-0.69	-0.77	-0.89	-0.95	-1.07	-1.09	-1.08	-1.18	-1.19	-1.12	-	-
Free Cashflow	-698.1%	-3,585,000	-449,206	-6,892,592	-2,452,828	-6,832,356	-20,192,674	-5,274,499	-6,706,131	-3,428,763	-5,475,500	-691,087	-4,132,450

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-5.0%	30,088	31,679	35,611	43,724	42,226	49,950	25,412	31,596	39,633	44,202	27,282	6,532
Current Assets	-3.4%	16,505	17,085	16,817	23,749	20,078	26,538	10,345	15,749	22,879	26,992	10,166	2,180
Cash Equivalents	1087.0%	13,612	1,147	3,018	8,726	6,175	13,765	4,748	9,085	14,108	25,934	1,191	1,818
Net PPE	-5.2%	579	611	662	716	1,345	1,506	737	762	922	890	721	195
Goodwill	0.0%	3,018	3,018	6,035	6,035	5,873	5,837	2,383	2,383	2,383	2,383	1,676	-
Liabilities	-1.2%	44,584	45,117	44,853	46,393	44,137	43,815	11,425	12,526	15,165	14,493	22,667	10,028
Current Liabilities	-3.5%	20,123	20,843	20,447	22,233	17,458	17,360	8,650	9,535	11,967	11,145	14,728	2,649
Shareholder's Equity	-7.9%	-14,496	-13,438	-	-	-1,911	6,134	13,988	19,070	24,468	29,708	4,615	-
Retained Earnings	-5.7%	-81,092	-76,746	-71,700	-64,423	-56,866	-47,994	-39,460	-33,680	-27,015	-21,525	-15,797	-5,540
Additional Paid-In Capital	5.2%	66,595	63,307	62,476	61,754	54,954	54,128	53,446	52,749	51,481	51,232	20,411	2,044
Shares Outstanding	29.4%	10,301	7,961	7,811	7,256	21,413	5,320	5,087	4,962	4,907	5,075	1,962	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-698.1%	-3,585	-449	-6,600	-2,160	-6,539	-19,900	-5,216	-6,794	-3,327	-5,268	-650	-4,115	-760	-	-
Share Based Compensation	114.4%	561	262	847	367	623	673	689	1,078	666	269	256	476	230	-	-
Cashflow From Investing	-100.0%	-	1,000	9.00	15.00	3.00	33,303	-260	-125	-494	-462	-279	10,895	-509	-	-
Cashflow From Financing	377.4%	3,705	-1,335	146*	6,432	221*	-	-	-	-	22,664	2,050	178	376	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MRAI Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Revenue

$ 7,385

$ 9,672

Costs and expenses

Cost of revenue (exclusive of depreciation and amortization shown separately below)

4,871

6,409

General and administrative

3,421

5,226

Sales and marketing

602

2,179

Information technology

1,124

2,187

Research and development

500

Depreciation and amortization

951

1,044

Facilities

474

650

Total costs and expenses

11,450

18,195

Operating loss

(4,065)

(8,523)

Other income (expenses)

Other income

120

Interest expense net

(398)

(385)

Foreign exchange loss

(3)

(15)

Loss before provision for income taxes

(4,346)

(8,873)

Net loss

$ (4,346)

$ (8,873)

Net loss per share, basic

^[1]

$ (0.46)

$ (1.68)

Net loss per share, fully diluted

^[1]

$ (0.46)

$ (1.68)

Weighted average shares of common stock outstanding, basic

9,405,775

5,290,661

^[1]

Weighted average shares of common stock outstanding, diluted

9,405,775

5,290,661

^[1]

[1]	Reflects1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

MRAI Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents

$ 851

$ 1,147

Restricted cash

12,761

12,345

Accounts receivable, net

366

1,124

Unbilled receivable

727

768

Prepaid expenses and other current assets

1,000

901

Total current assets

16,505

17,085

Property and equipment, net

579

611

Capitalized software, net

1,512

2,127

Operating lease right-of-use assets

2,311

2,373

Goodwill

3,018

Intangible assets, net

4,874

5,177

Security deposits

1,267

Other long-term asset

Total assets

30,088

31,680

Current liabilities:

Accounts payable

3,824

4,649

Accrued expenses

3,076

2,816

Accrued fiduciary obligations

9,510

11,573

Deferred revenue

1,481

661

Current portion of operating lease liabilities

523

512

Total current liabilities

20,123

20,843

Other long-term liabilities

19,724

19,401

Operating lease liabilities, net of current portion

3,547

3,684

Deferred tax liabilities

1,190

Total liabilities

44,584

45,118

COMMITMENTS AND CONTINGENCIES (Note 16)

STOCKHOLDERS' DEFICIT

Common stock, $0.0001 par value, 227,791,050 shares authorized; 10,308,038 shares and 7,960,938 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively

^[1]

Additional paid-in capital

66,595

63,307

Accumulated deficit

(81,092)

(76,746)

Total stockholders' deficit

(14,496)

(13,438)

Total liabilities and stockholders' deficit

30,088

31,680

Nonrelated Party

Current liabilities:

Other short-term liabilities

1,709

632

Related Party

Current assets:

Other receivables

$ 800

[1]	Reflects1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

About Marpai, Inc.

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, bill review and cost containment services. It also develops artificial intelligence and healthcare technology. Marpai, Inc. was incorporated in 2021 and is headquartered in New York, New York.

CEO	Mr. Edmundo Gonzalez
WEBSITE	marpaihealth.com
INDUSTRY	Healthcare Plans
EMPLOYEES	303

Marpai, Inc. Frequently Asked Questions

What is the ticker symbol for Marpai, Inc.? What does MRAI stand for in stocks?

MRAI is the stock ticker symbol of Marpai, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Marpai, Inc. (MRAI)?

As of Fri May 17 2024, market cap of Marpai, Inc. is 21.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRAI stock?

You can check MRAI's fair value in chart for subscribers.

What is the fair value of MRAI stock?

You can check MRAI's fair value in chart for subscribers. The fair value of Marpai, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Marpai, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRAI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Marpai, Inc. a good stock to buy?

The fair value guage provides a quick view whether MRAI is over valued or under valued. Whether Marpai, Inc. is cheap or expensive depends on the assumptions which impact Marpai, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRAI.

What is Marpai, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MRAI's PE ratio (Price to Earnings) is -0.89 and Price to Sales (PS) ratio is 0.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRAI PE ratio will change depending on the future growth rate expectations of investors.